Literature DB >> 33446516

Complement Drives Synaptic Degeneration and Progressive Cognitive Decline in the Chronic Phase after Traumatic Brain Injury.

Ali Alawieh1,2, Reda M Chalhoub1,3, Khalil Mallah1, E Farris Langley1, Mikaela York1, Henry Broome1, Christine Couch1, DeAnna Adkins3,4, Stephen Tomlinson5,4.   

Abstract

Cognitive deficits following traumatic brain injury (TBI) remain a major cause of disability and early-onset dementia, and there is increasing evidence that chronic neuroinflammation occurring after TBI plays an important role in this process. However, little is known about the molecular mechanisms responsible for triggering and maintaining chronic inflammation after TBI. Here, we identify complement, and specifically complement-mediated microglial phagocytosis of synapses, as a pathophysiological link between acute insult and a chronic neurodegenerative response that is associated with cognitive decline. Three months after an initial insult, there is ongoing complement activation in the injured brain of male C57BL/6 mice, which drives a robust chronic neuroinflammatory response extending to both hemispheres. This chronic neuroinflammatory response promotes synaptic degeneration and predicts progressive cognitive decline. Synaptic degeneration was driven by microglial phagocytosis of complement-opsonized synapses in both the ipsilateral and contralateral brain, and complement inhibition interrupted the degenerative neuroinflammatory response and reversed cognitive decline, even when therapy was delayed until 2 months after TBI. These findings provide new insight into our understanding of TBI pathology and its management; and whereas previous therapeutic investigations have focused almost exclusively on acute treatments, we show that all phases of TBI, including at chronic time points after TBI, may be amenable to therapeutic interventions, and specifically to complement inhibition.SIGNIFICANCE STATEMENT There is increasing evidence of a chronic neuroinflammatory response after traumatic brain injury (TBI), but little is known about the molecular mechanisms responsible for triggering and maintaining chronic inflammation. We identify complement, and specifically complement-mediated microglial phagocytosis of synapses, as a pathophysiological link between acute insult and a chronic neurodegenerative response, and further that this response is associated with cognitive decline. Complement inhibition interrupted this response and reversed cognitive decline, even when therapy was delayed until 2 months after injury. The data further support the concept that TBI should be considered a chronic rather than an acute disease condition, and have implications for the management of TBI in the chronic phase of injury, specifically with regard to the therapeutic application of complement inhibition.
Copyright © 2021 the authors.

Entities:  

Keywords:  cognitive recovery; complement; neuroinflammation; therapy; traumatic brain injury

Year:  2021        PMID: 33446516      PMCID: PMC8115878          DOI: 10.1523/JNEUROSCI.1734-20.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.

Authors:  Stephen W Scheff; Douglas A Price; Frederick A Schmitt; Elliott J Mufson
Journal:  Neurobiol Aging       Date:  2005-11-09       Impact factor: 4.673

2.  G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.

Authors:  Franz Faul; Edgar Erdfelder; Albert-Georg Lang; Axel Buchner
Journal:  Behav Res Methods       Date:  2007-05

3.  Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury.

Authors:  T Kossmann; P F Stahel; M C Morganti-Kossmann; J L Jones; S R Barnum
Journal:  J Neuroimmunol       Date:  1997-03       Impact factor: 3.478

4.  Cognitive rehabilitation for traumatic brain injury: A randomized trial. Defense and Veterans Head Injury Program (DVHIP) Study Group.

Authors:  A M Salazar; D L Warden; K Schwab; J Spector; S Braverman; J Walter; R Cole; M M Rosner; E M Martin; J Ecklund; R G Ellenbogen
Journal:  JAMA       Date:  2000-06-21       Impact factor: 56.272

5.  Blood-brain barrier disruption in post-traumatic epilepsy.

Authors:  O Tomkins; I Shelef; I Kaizerman; A Eliushin; Z Afawi; A Misk; M Gidon; A Cohen; D Zumsteg; A Friedman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-11-08       Impact factor: 10.154

6.  Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice.

Authors:  Mario Rancan; Maria C Morganti-Kossmann; Scott R Barnum; Silvia Saft; Oliver I Schmidt; Wolfgang Ertel; Philip F Stahel
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

7.  Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice.

Authors:  Ali Alawieh; E Farris Langley; Stephen Tomlinson
Journal:  Sci Transl Med       Date:  2018-05-16       Impact factor: 17.956

8.  Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist.

Authors:  Diane L Sewell; Brendon Nacewicz; Frances Liu; Sinarack Macvilay; Anna Erdei; John D Lambris; Matyas Sandor; Zsuzsa Fabry
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

9.  Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice.

Authors:  Philip F Stahel; Michael A Flierl; B Paul Morgan; Ivonne Persigehl; Christiane Stoll; Claudia Conrad; Basel M Touban; Wade R Smith; Kathryn Beauchamp; Oliver I Schmidt; Wolfgang Ertel; Iris Leinhase
Journal:  J Neuroinflammation       Date:  2009-01-08       Impact factor: 8.322

Review 10.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

View more
  8 in total

1.  Complement factor C1q mediates sleep spindle loss and epileptic spikes after mild brain injury.

Authors:  Stephanie S Holden; Fiorella C Grandi; Oumaima Aboubakr; Bryan Higashikubo; Frances S Cho; Andrew H Chang; Alejandro Osorio Forero; Allison R Morningstar; Vidhu Mathur; Logan J Kuhn; Poojan Suri; Sethu Sankaranarayanan; Yaisa Andrews-Zwilling; Andrea J Tenner; Anita Luthi; Eleonora Aronica; M Ryan Corces; Ted Yednock; Jeanne T Paz
Journal:  Science       Date:  2021-09-10       Impact factor: 63.714

2.  Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury.

Authors:  Inge A M van Erp; Iliana Michailidou; Thomas A van Essen; Mathieu van der Jagt; Wouter Moojen; Wilco C Peul; Frank Baas; Kees Fluiter
Journal:  Neurotherapeutics       Date:  2022-10-12       Impact factor: 6.088

3.  Tandem Mass Tag-based proteomics analysis reveals the vital role of inflammation in traumatic brain injury in a mouse model.

Authors:  Jin-Qian Dong; Qian-Qian Ge; Sheng-Hua Lu; Meng-Shi Yang; Yuan Zhuang; Bin Zhang; Fei Niu; Xiao-Jian Xu; Bai-Yun Liu
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

4.  Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.

Authors:  Donald V Bradshaw; Andrew K Knutsen; Alexandru Korotcov; Genevieve M Sullivan; Kryslaine L Radomski; Bernard J Dardzinski; Xiaomei Zi; Dennis P McDaniel; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

5.  Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study.

Authors:  Amer Toutonji; Mamatha Mandava; Silvia Guglietta; Stephen Tomlinson
Journal:  Acta Neuropathol Commun       Date:  2021-07-19       Impact factor: 7.578

6.  Complement mediates neuroinflammation and cognitive decline at extended chronic time points after traumatic brain injury.

Authors:  Khalil Mallah; Christine Couch; Mohammed Alshareef; Davis Borucki; Xiaofeng Yang; Ali Alawieh; Stephen Tomlinson
Journal:  Acta Neuropathol Commun       Date:  2021-04-20       Impact factor: 7.578

7.  Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation.

Authors:  Chaowen Zheng; Jerec Ricci; Qinqin Zhang; Ali Alawieh; Xiaofeng Yang; Satish Nadig; Songqing He; Pablo Engel; Junfei Jin; Carl Atkinson; Stephen Tomlinson
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

Review 8.  Neuroinflammation Following Traumatic Brain Injury: Take It Seriously or Not.

Authors:  Rui-Zhe Zheng; Kuin-Yu Lee; Zeng-Xin Qi; Zhe Wang; Ze-Yu Xu; Xue-Hai Wu; Ying Mao
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.